STOXPO
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
  • Latest News
  • Technology
    • Software
    • Semiconductors
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions
No Result
View All Result
STOXPO
No Result
View All Result
Home Healthcare Pharmaceuticals
scientist

Telomir Pharmaceuticals Unveils Groundbreaking Results in Age-Reversal Science with Telomir-1

byLuca Blaumann
November 21, 2024
in Pharmaceuticals, Small-Cap
Reading Time: 5 mins read
Share on TwitterShare on LinkedIn

Preclinical Study Highlights Significant Longevity Benefits, Sets Stage for Human Trials

Telomir Pharmaceuticals (Nasdaq: TELO) has announced groundbreaking preclinical results that may redefine age-reversal science and longevity treatments. Its flagship compound, Telomir-1, demonstrated substantial efficacy in a preclinical study, extending lifespan, improving mobility, and reversing age-related decline in aging model organisms. With this promising data, Telomir Pharmaceuticals is advancing closer to human trials, positioning Telomir-1 as a potential game-changer in treating age-related diseases and enhancing life quality.

Breakthrough Preclinical Results Using Telomir-1

The study, conducted in collaboration with Switzerland-based Nagi Biosciences SA, used advanced microfluidic technology to analyze the effects of Telomir-1 on the well-known model organism, Caenorhabditis elegans. With real-time, automated monitoring of critical metrics like lifespan, health span, and age-related mobility, the microfluidic platform allowed precise tracking of biological aging.

According to Dr. Laurent Mouchiroud, Chief Scientific Officer at Nagi Biosciences, “We are thrilled to contribute to this groundbreaking study through our innovative microfluidic technology, which allows precise and automated monitoring of aging and healthspan metrics in real-time. These results highlight Telomir-1’s remarkable potential to improve longevity and health, showcasing the power of cutting-edge tools in advancing age-reversal science.”

The preclinical findings revealed several key insights into Telomir-1’s potential:

  • Enhanced Mobility in Older Organisms: Telomir-1 was shown to improve movement in older model organisms, suggesting the compound slows aging. Mobility, a primary indicator of health, showed marked improvements, especially in later life stages.
  • Reversal of Biological Aging: The study demonstrated that Telomir-1 could reverse biological age markers. This significant finding supports Telomir-1’s potential to slow and even reverse biological aging, making it a promising candidate for age-reversal therapies.
  • Extended Lifespan: The data showed a statistically significant increase in lifespan in treated populations, further confirming Telomir-1’s potential role in promoting longevity.

“These findings establish a promising foundation for Telomir-1 as a transformative treatment in age-reversal science,” commented Dr. Itzchak Angel, Chief Scientific Advisor at Telomir Pharmaceuticals. “This study confirms that Telomir-1 not only extends life but also supports healthier aging, as evidenced by improvements in mobility and reduced age-related decline.”

Telomir’s Strategic Path: Targeting Rare Diseases and Broader Applications

The implications of Telomir-1’s effectiveness are not limited to general longevity; the company is also targeting specific diseases marked by accelerated aging, such as progeria. Telomir has launched collaborations with the Progeria Foundation to evaluate the effects of Telomir-1 on human progeria cell lines, directly investigating its potential to counteract the cellular aging associated with this rare condition.

An additional study using progeria-modeled Caenorhabditis elegans will explore Telomir-1’s impact on progeria from an organismal perspective. Together, these studies aim to provide valuable insights into Telomir-1’s potential to treat age-related diseases on both cellular and whole-organism levels.

“Our research is intensifying around progeria due to its accelerated aging effects, which make it an ideal focus for Telomir-1,” said Erez Aminov, Chairman and CEO of Telomir Pharmaceuticals. “We believe these studies will highlight Telomir-1’s potential to address progeria at a fundamental level, making it a prime candidate for therapeutic interventions targeting genetic aging.”

Expanding Research into Age-Related Diseases and Veterinary Applications

In addition to progeria, Telomir Pharmaceuticals is investigating the applications of Telomir-1 in combating chronic diseases such as diabetes, cancer, and inflammatory conditions. This expanded research agenda underscores Telomir’s commitment to leveraging Telomir-1’s age-reversal capabilities for a wide range of medical conditions beyond general aging.

“We are currently scaling up API production and drug manufacturing while optimizing our Chemistry, Manufacturing, and Controls (CMC) efforts,” shared Aminov. “In parallel, we are conducting preclinical studies on diabetes, cancer, and other age-related inflammatory conditions, as well as further research in progeria models. We are also assessing Telomir-1 for Alzheimer’s and other age-reversal models.”

In a strategic move, Telomir Pharmaceuticals is also pursuing veterinary applications, beginning with studies on aging dogs with osteoarthritis. This approach follows a dual regulatory pathway involving both Investigational New Animal Drug (INAD) and Investigational New Drug (IND) applications, setting the stage for human and animal treatment options. “We are planning a study in aging dogs with osteoarthritis and pursuing a dual path with an INAD application for animals, alongside the IND application for humans,” Aminov added.

Safety studies in rats and dogs are underway, with the company on track to submit the IND application by mid-2025 and begin Phase I human trials by year-end 2025. According to Aminov, “Our goal remains to bring Telomir-1 into clinical stages as soon as possible, backed by thorough preclinical evidence of both safety and efficacy.”

Pioneering Age-Reversal Science with Visionary Goals

With its latest findings, Telomir Pharmaceuticals is firmly establishing itself as an innovative force in age-reversal science. The promising preclinical data on Telomir-1 supports its potential as a multifaceted therapeutic candidate for both rare and common age-related conditions.

By addressing the fundamental biological mechanisms of aging, Telomir-1 has the potential to profoundly impact patient care, offering new hope for managing age-related diseases while enhancing life quality. Telomir’s commitment to developing solutions for age-associated ailments highlights its dedication to expanding the scope of longevity science beyond traditional boundaries.

Telomir’s upcoming collaborations and preclinical initiatives exemplify its ambitious plans for advancing age-reversal science and combating aging-related diseases. With the path toward human trials in sight, Telomir Pharmaceuticals continues to pioneer treatments that may soon redefine how society approaches aging.

“Our journey with Telomir-1 represents a revolutionary approach to longevity, and we are dedicated to bringing these scientific advancements into practical applications that can benefit humanity,” Aminov concluded. “These preclinical findings not only demonstrate Telomir-1’s potential but also reinforce our commitment to creating transformative, life-extending treatments. We are excited about what lies ahead as we continue to unlock the possibilities of age-reversal science.”

As Telomir Pharmaceuticals pushes forward, the medical and scientific communities will watch closely, eager to see how Telomir-1 can contribute to the ultimate goal of reversing the biological clock and expanding health and longevity for future generations.

Read the original press release here

You might like this article:Bitcoin on the Brink of $100,000 as Trump’s Support Sparks Regulatory Optimism

Tags: GrowthMoversNewsPharmaceuticalsStock Market
Previous Post

Bitcoin on the Brink of $100,000 as Trump’s Support Sparks Regulatory Optimism

Next Post

Worksport Addresses Unusual Stock Activity Amid Record Growth and New Product Launches

Related Posts

opthalmology

Telomir Pharmaceuticals Reports Breakthrough in Oral Therapy for Vision Loss

byLiliana Vida
May 29, 2025
0

Telomir-1 reverses retinal degeneration and restores vision in advanced AMD zebrafish model Telomir Pharmaceuticals (TELO) announced a major preclinical breakthrough...

Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program

byLuca Blaumann
May 21, 2025
0

Insider-Led Funding with No Warrants Strengthens Balance Sheet Ahead of IND Submission for Telomir-1 Telomir Pharmaceuticals (TELO), a biotech innovator...

Institutional Interest In Telomir Pharmaceuticals

byLiliana Vida
May 13, 2025
0

Telomir Pharmaceuticals (TELO) has caught the attention of institutional investors, with JPMorgan Chase & Co. (JPM) significantly increasing its position...

Next Post
investing

Worksport Addresses Unusual Stock Activity Amid Record Growth and New Product Launches

Latest News

UnitedHealth CEO Vows to Regain Shareholder Trust After Rare Earnings Miss

Marvell Projects Strong Q2 Growth on AI Chip Demand Surge

Nvidia Surges as AI Momentum Outweighs China Setbacks in Q1 Earnings

Telomir Pharmaceuticals Reports Breakthrough in Oral Therapy for Vision Loss

Macy’s Beats Q1 Estimates But Cuts 2025 Outlook Amid Retail Headwinds

Based on Your Interest

bitcoin-3
Bitcoin

Bitcoin Smashes Through $111K Amid Regulatory Optimism and Institutional Demand

May 22, 2025
Pharmaceuticals

Telomir Pharmaceuticals Secures $3M Premium Equity Investment to Advance Rare Disease Program

May 21, 2025
tesla-2
Mega-Cap

Elon Musk Confirms Tesla and xAI to Continue Buying AI Chips from Nvidia and AMD

May 21, 2025

Recommended

Aerospace & Defense

KULR Expands Bitcoin Treasury to $78 Million, Strengthens Crypto-Centric Financial Strategy

May 20, 2025
Internet

Reddit Stock: Undervalued Gem in the Social Media Landscape

May 20, 2025
Large-Cap

AMD to Sell ZT Systems Manufacturing Business to Sanmina in $3 Billion Deal

May 19, 2025
Large-Cap

Dick’s Sporting Goods to Acquire Foot Locker in $2.4 Billion Deal

May 16, 2025
Large-Cap

AMD Expands Stock Buyback Program to $10 Billion Amid Strong Financial Confidence

May 14, 2025
Stoxpo

Follow us on social media:

Highlights

  • UnitedHealth CEO Vows to Regain Shareholder Trust After Rare Earnings Miss
  • Marvell Projects Strong Q2 Growth on AI Chip Demand Surge
  • Nvidia Surges as AI Momentum Outweighs China Setbacks in Q1 Earnings
  • Telomir Pharmaceuticals Reports Breakthrough in Oral Therapy for Vision Loss
  • Macy’s Beats Q1 Estimates But Cuts 2025 Outlook Amid Retail Headwinds

Category

  • Blog
  • Communication Services
    • Entertainment
    • Internet
    • Telecommunications
  • Companies
    • Large-Cap
    • Mega-Cap
    • Micro-Cap
    • Mid-Cap
    • Small-Cap
  • Consumer Cyclical
    • Auto Manufacturers
    • Casinos & Gambling
    • Ground Transportation
    • Hospitality
      • Casinp
      • Resorts & Lodging
      • Restaurants
      • Travel
        • Airlines
    • Retail
    • Textiles, Apparel & Luxury Goods
  • Consumer Defensive
    • Beverages
    • Discount Stores
    • Distributor
    • Ecommerece
    • Electrical Equipment
    • Foods
    • Household & Personal Products
    • Leisure Products
    • Tobacco
  • Contributions
  • Crypto
    • Altcoins
    • Bitcoin
    • Ethereum
  • Economy
  • Energy
    • Electric
    • Oil & Gas
    • Renewables
  • Financial Services
    • Asset Management
    • Banks
    • Brokerages
    • Credit Services
    • Insurance
  • Healthcare
    • Biotechnology
    • Medical Devices
    • Pharmaceuticals
  • Industrials
    • Aerospace & Defense
    • Construction
    • Industrial Machinery
  • Materials
    • Building Materials
    • Chemicals
    • Gold
    • Mining
    • Silver
    • Steel
  • Q&A's
  • Real Estate
  • Technology
    • Artificial Intelligence
    • Computer Hardware
    • Consumer Electronics
    • Cybersecurity
    • IT Services
    • Semiconductors
    • Software
  • Utilities

Latest News

UnitedHealth CEO Vows to Regain Shareholder Trust After Rare Earnings Miss

June 2, 2025
investing

Marvell Projects Strong Q2 Growth on AI Chip Demand Surge

May 29, 2025
semiconductor-2

Nvidia Surges as AI Momentum Outweighs China Setbacks in Q1 Earnings

May 29, 2025
  • About
  • Privacy Policy
  • Contact

© 2024 All Rights Reserved: STOXPO.

No Result
View All Result
  • Latest News
  • Healthcare
    • Biotechnology
    • Pharmaceuticals
  • Technology
    • Software
    • Semiconductors
  • Crypto
    • Bitcoin
    • Ethereum
    • Altcoins
  • Companies
    • Micro-Cap
    • Small-Cap
    • Mid-Cap
    • Large-Cap
    • Mega-Cap
  • Q&A’s
  • Contributions

© 2024 All Rights Reserved: STOXPO.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read More

In case of sale of your personal information, you may opt out by using the link Do Not Sell My Personal Information

Accept Cookie Settings
Cookies are small text files that can be used by websites to make a user's experience more efficient. The law states that we can store cookies on your device if they are strictly necessary for the operation of this site. For all other types of cookies we need your permission. This site uses different types of cookies. Some cookies are placed by third party services that appear on our pages.
  • Always Active
    Necessary
    Necessary cookies help make a website usable by enabling basic functions like page navigation and access to secure areas of the website. The website cannot function properly without these cookies.
  • Marketing
    Marketing cookies are used to track visitors across websites. The intention is to display ads that are relevant and engaging for the individual user and thereby more valuable for publishers and third party advertisers.
  • Analytics
    Analytics cookies help website owners to understand how visitors interact with websites by collecting and reporting information anonymously.
  • Preferences
    Preference cookies enable a website to remember information that changes the way the website behaves or looks, like your preferred language or the region that you are in.
  • Unclassified
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
Cookie Settings

Do you really wish to opt-out?